United States - English - NLM (National Library of Medicine)

ajenat pharmaceuticals llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics. pregnancy category c animal reproduction studies have not been conducted with potassium chloride. it is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. the normal potassium ion content of human milk is about 13 meq per liter. since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition f

United States - English - NLM (National Library of Medicine)

sj pharmaceuticals, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv) - methenamine 120 mg in 170.92 mg

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - carprofen (unii: ffl0d546ho) (carprofen - unii:ffl0d546ho) - belprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. belprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - carprofen (unii: ffl0d546ho) (carprofen - unii:ffl0d546ho) - belprofen is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. belprofen should not be used in dogs exhibiting previous hypersensitivity to carprofen.

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - midazolam hydrochloride (unii: w7ttw573jj) (midazolam - unii:r60l0sm5bc) - midazolam injection is indicated: •  intramuscularly or intravenously for preoperative sedation/anxiolysis/amnesia; •  intravenously as an agent for sedation/anxiolysis/amnesia prior to or during diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography, cardiac catheterization, oncology procedures, radiologic procedures, suture of lacerations and other procedures either alone or in combination with other cns depressants; •  intravenously for induction of general anesthesia, before administration of other anesthetic agents. with the use of narcotic premedication, induction of anesthesia can be attained within a relatively narrow dose range and in a short period of time. intravenous midazolam can also be used as a component of intravenous supplementation of nitrous oxide and oxygen (balanced anesthesia); •  continuous intravenous infusion for sedation of intubated and mechanically ventilated patients as a component of anesthesia or during treatment in a critical care setting. injectable midazolam hydrochloride is contraindicated in patients with a known hypersensitivity to the drug. benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction with midazolam hydrochloride; patients with glaucoma have not been studied. midazolam hydrochloride is not intended for intrathecal or epidural administration due to the presence of the preservative benzyl alcohol in the dosage form. midazolam hydrochloride is contraindicated for use in premature infants because the formulation contains benzyl alcohol (see warnings and precautions, pediatric use ). midazolam hydrochloride contains midazolam, a schedule iv control substance. midazolam was actively self-administered in primate models used to assess the positive reinforcing effects of psychoactive drugs. midazolam produced physical dependence of a mild to moderate intensity in cynomolgus monkeys after 5 to 10 weeks of administration. available data concerning the drug abuse and dependence potential of midazolam suggest that its abuse potential is at least equivalent to that of diazepam. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuation of benzodiazepines, including midazolam. abdominal distention, nausea, vomiting, and tachycardia are prominent symptoms of withdrawal in infants. the more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. generally milder withdrawal symptoms (e.g., dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. there is no consensus in the medical literature regarding tapering schedules; therefore, practitioners are advised to individualize therapy to meet patient’s needs. in some case reports, patients who have had severe withdrawal reactions due to abrupt discontinuation of high-dose long-term midazolam, have been successfully weaned off of midazolam over a period of several days.

United States - English - NLM (National Library of Medicine)

virtus pharmaceuticals - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hydrochloride/clidinium bromide is indicated to control the emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hydrochloride/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hydrochloride/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have

United States - English - NLM (National Library of Medicine)

bpi labs llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics. pregnancy category c animal reproduction studies have not been conducted with potassium chloride. it is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. the normal potassium ion content of human milk is about 13 meq per liter. since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. clinical trial data from published literature have demonstrated the safety and effectiveness of potassium chloride in children with diarrhea and malnutrition f

United States - English - NLM (National Library of Medicine)

petiq, llc - carprofen (unii: ffl0d546ho) (carprofen - unii:ffl0d546ho) - indications: truprofen flavored tab is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs. contraindications: truprofen flavored tab should not be used in dogs exhibiting previous hypersensitivity to carprofen.

United States - English - NLM (National Library of Medicine)

northwind pharmaceuticals - cephalexin (unii: obn7uds42y) (cephalexin anhydrous - unii:5sff1w6677) - cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: respiratory tract infections caused by streptococcus pneumoniae and streptococcus pyogenes (penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) otitis media due to streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus pyogenes, and moraxella catarrhalis skin and skin structure infections caused by staphylococcus aureus and/or streptococcus pyogenes bone infections caused by staphylococcus aureus and/or proteus mirabilis genitourinary tract infections, including acute prostatitis, caused by escherichia coli,

United States - English - NLM (National Library of Medicine)

edwards pharmaceuticals, inc. - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic (unii: 3980jih2sw) (sodium cation - unii:lyr4m0nh37), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - methenamine 81.6 mg - urogesic-blue™ is indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as hypermotility which accompany lower urinary tract infections and as antispasmodic. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. urogesic-blue™ is contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrythmias, congestive heart failure, coronary heart disease, mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy). a dependence on the use of urogesic-blue™ has not been reported and due to the nature of its ingredients, abuse of urogesic-blue™ is not expected.